The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors.
The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines.
The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her.
Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients.
To view the multimedia release go to:
http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
Team In Training. Light The Night. Man & Woman of the Year. Student Series. Leukemia Cup Regatta. More than 13 million participants in these popular fundraising campaigns last year alone helped The Leukemia & Lymphoma Society (LLS) invest more than $1 billion in research to advance lifesaving treatments and cures for blood cancer patients.
For Blood Cancer Awareness Month this September, LLS is reminding us that despite progress, much work still needs to be done to save more lives. More than 1.2 million people in the U.S. are living with or in remission from a blood cancer. Leukemia causes more deaths than any other cancer among children, adolescents and adults younger than 20 years. Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 58,320 people in the U.S. in 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554853-lls-blood-cancer-awareness-month/
Northwestern Mutual, presenting sponsor of the 2016 Rose Bowl Game®, today unveiled its float design for the 127th Rose Parade® presented by Honda. Titled Dancing into Adventure, it will draw attention to the fight against childhood cancer by showcasing the greatest adventure and dream of Peyton Richardson, a 13-year-old aspiring ballerina from Sugar Land, Texas, who is battling leukemia.
The theme of this year’s parade is Find Your Adventure. As an aspiring ballerina, Peyton wants to travel the world to see performances from the world’s most distinguished ballet companies and have a dance lesson with their principal dancers. Northwestern Mutual is using its sponsorship to bring Peyton’s adventure to life in flowers and raise awareness about childhood cancer.
“Peyton’s unique, positive way of using ballet to battle cancer and stay focused on her dream is truly amazing,” said Conrad York, vice president of marketing at Northwestern Mutual. “At Northwestern Mutual, we know that each family has a dream in mind for their future, and we are here to support them every step of the way.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7422155-northwestern-mutual-rose-parade-float/
Every three minutes someone in the U.S. is diagnosed with a blood cancer. No one knows this better than “Nashville” star Charles Esten and his wife Patty. Esten’s 15-year-old daughter, Addie, was diagnosed with leukemia at age 2 ½. Naturally, their world was turned upside down. But, they quickly learned that there was hope, based on research to advance new treatments and cures for leukemia, much of it funded by The Leukemia & Lymphoma Society (LLS).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7491051-charles-esten-light-the-night-walks/
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
St. Jude Children’s Research Hospital patients who completed kindergarten during their treatment for pediatric cancers celebrated at a graduation ceremony.
For the 10th straight year, St. Jude honored 14 patients from around the United States who completed kindergarten while battling life-threatening illnesses like leukemia and brain tumors. Dozens of families and St. Jude doctors, nurses, and staff cheered for the young students, who completed kindergarten in the St. Jude School Program by Chili’s.
Each year, the school program commemorates students who have completed kindergarten coursework with a special ceremony. The children present a song for the families and St. Jude staff, receive their diplomas and celebrate the milestone with their fellow students.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924755-st-jude-celebrates-kindergarten-graduation/
As breakthroughs in cancer treatments are occurring at an ever increasing rate, The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances.
Through its significant investment in cancer research – more than $1.2 billion since its founding nearly 70 years ago – LLS is committed to funding and recognizing female scientists, physicians, social workers and nurses, and encouraging young women to participate in STEM (science, technology, engineering and math) education and pursue careers in the sciences.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128552-lls-women-in-science/
